PATIENT-HOTLINE

Patients and relatives can contact short at this point of contact for questions, suggestions and criticism.

+49 (0) 89 660 680

We are there for you at the following times

Monday to Friday from 8.00 am to 6.00 pm

Contact

RINECKER PROTON THERAPY CENTER
Franz-von-Rinecker Straße (main entrance)

Schäftlarnstraße 133 (postal address)

81371 München

Do you have any questions?
+49 (0) 89 660680

About us

The RINECKER PROTON THERAPY CENTER

The RPTC, located in Munich, is the first fully certified European proton radiation center which provides a complete hospital setting for the treatment of cancer tumors.

Our innovative therapeutic procedure involves the use of high-energy proton beams for the treatment of cancer. A key characteristic of these proton beams is that protons facilitate the three-dimensional targeting of tumours; this capability is not available with the x-rays used in conventional radiation therapy. Therefore, highly effective dosages can be delivered to the tumour while the side effects of radiation are reduced by minimizing any trauma to the surrounding healthy tissue.

Questions? +49 (0) 89 660 680

Tumor Board of Specialists

Oncology (from the Greek onkos, or mass), the science of malignant tumors, is not a separate specialization; many different specialists work in oncology. According to conventional methodology, these are internal specialists, surgeons and radiotherapists. However, depending on the affected organs, other specialists may be involved, including gynecologists, neurosurgeons, urologists, gastroenterologists, ENT specialists and opthalmologists. Thus, it seems prudent that the specialists involved should also manage the treatment together.
 
The Center has set up a Tumor Board for this purpose. In special cases, the Board is consulted to review therapeutic decisions. Specialists in radiotherapy, radiodiagnostics (these two sub-specialties are differentiated in medicine), surgery, internal medicine-specific oncology, and pathology are permanent members of the Tumor Board.

Your attending physician remains responsible

The radiotherapy specialist looking after you is responsible for managing your treatment. It is his or her responsibility to ensure that your opinion as a patient and all findings obtained at the Center are taken into account. If you, as the patient, are referred by a physician or hospital performing treatment, there will be a consultation with that physician or hospital.

The radiotherapy specialist‘s deliberations will result in one of four decisions, which must also have the consensus of the Tumor Board:

  • Proton therapy doesn't make sense. The attending physician is then obliged to start an alternative treatment wherever and with whomever is appropriate.

  • Proton therapy makes sense as the sole therapy. The therapy is then planned as described above. Treatment remains in the hands of the proton specialists, while the Tumor Board does not conduct an individual consultation in this situation. However, the Tumor Board reviews every case and monitors compliance with quality standards.

  • Proton therapy makes sense, but there is a competing alternative therapy. This is a typical situation where the Tumor Board will discuss the case before radiation treatment begins.

  • Proton therapy makes sense, but it should be given in combination with another form of therapy (such as chemotherapy or surgery). Cases of this nature are also discussed in detail by the Tumor Board before a final decision on therapy is made.

Tumor Board discussion serves to support the therapy decision of the attending physician or make an alternative recommendation where appropriate.

Members of the tumor board

Abdominal Surgery Dr. Steitz (Chirurgisches Klinikum München Süd)
Breast Center Dr. Funke (Chirurgisches Klinikum München Süd)
Neurosurgery Prof. Dr. Tonn (LMU München)
Urology Dr. Voigt, Praxis München
Gastroenterology Prof. Groß, Internistische Klinik Dr. Müller
Hematology-Oncology Dr. Walther, Praxis Internistische Klinik Dr. Müller
Pathology Prof. Dr. Dr. habil. Walter Natrath
Pediatric Oncology Prof. Burdach, Kinderklinik Schwabing, TU München Rechts der Isar
Copyright © 2017 Pro Health AG